Search Results 9411-9420 of 42384 for oral

1. Robotic surgery - Doctors & Departments - Mayo Clinic

   ... Oral and throat cancer, Adenocarcinoma, Laryngeal cancer, Carotid body tumor, Tongue base cancer, Mouth tumor, Salivary gland cancer, Parotid cancer ...

2. Study to Evaluate the Safety, Tolerability and Preliminary Antitumor Activity of INCB059872 in Patients with Relapsed/Refractory Ewing Sarcoma - Mayo Clinic

   Inability of the participant to swallow and retain oral medication. Cardiovascular. Clinically significant or uncontrolled cardiac disease, including ...

3. Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial - Mayo Clinic

   * Note: subjects intolerant to aspirin may use warfarin, novel oral anticoagulants, or low dose molecular weight heparin. * REGISTRATION-INCLUSION CRITERIA: * ...

4. Vasculitis - Doctors and departments - Mayo Clinic

   ning mouth syndrome, Oral lichen planus, Skin cancer, Skin problems, Dermatitis, Hair loss, Morphea, Canker sores, Klippel-Trenaunay syndrome, Psoriasis ...

5. Diabetic nephropathy (kidney disease) - Doctors and departments - Mayo Clinic

   Research at Mayo Clinic in diabetic nephropathy includes developing new diagnostic and treatment tools, such as oral medicines that may help stop or delay ...

6. Surgery - Doctors - Mayo Clinic

   vascular surgery, Parotidectomy, Transoral laser microsurgery, Throat cancer, Oral and throat cancer, Mouth cancer, Thyroid cancer, Head and neck cancer ...

7. Efficacy And Safety Of Subcutaneous Dupilumab In Participants With Asthma/asthmatic Wheeze Aged 2 To <6 Years - Mayo Clinic

   Severe asthma with the need for chronic oral/systemic corticosteroid use ( > th continuous) at the time of screening enrollment. History of a systemic ...

8. A Study To Evaluate TVB-2640 And Trastuzumab Plus Paclitaxel Or Endocrine Therapy For Treating Patients With HER2 Positive Advanced Breast Cancer - Mayo Clinic

   Patient is unable to swallow oral medications or has impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption ...

9. The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease - Mayo Clinic

   ), or oral or intravenous antibiotics within 30 days or 5 half-lives, whichever is longer, prior to Day 1. Subjects will be allowed to take their chronic ...

10. A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors - Mayo Clinic

    Received oral or IV antibiotics within 2 weeks prior to Cycle 1 Day 1. Significant cardiovascular disease, such as New York Heart Association (NYHA) cardiac ...